Sector revisions Arrowhead Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 18/07/2025 BST			5-day change	1st Jan Change
16.76 ^USD	-11.09%		-8.47%	-10.85%

07-08	Arrowhead Pharmaceuticals, Inc., Q2 2025 Earnings Call, May 12, 2025
07-08	Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility (Composite)	Nbr of analysts
	ARROWHEAD PHARMACEUTICALS, INC.							14
	ARGENX SE							14
	WUXI APPTEC CO., LTD.							18
	BIONTECH SE							21
	INSMED INCORPORATED							18
	SUMMIT THERAPEUTICS INC.							9
	AKESO, INC.							20
	WUXI BIOLOGICS (CAYMAN) INC.							26
	GENMAB A/S							16
	EXELIXIS, INC.							19
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.							16
	VERONA PHARMA PLC							9
	LEGEND BIOTECH CORPORATION							19
	MADRIGAL PHARMACEUTICALS, INC.							14
	PHARMAESSENTIA CORPORATION							4
	SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.							2
	BIOCON LIMITED							20
	NUVALENT, INC.							10
	REMEGEN CO., LTD.							14
	Average							15
	Weighted average by Cap.							16